Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Renal, and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK1 drug discovery targeting the tissue kallikrein-kinin system. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | Human KLK1 Recombinant Protein HEK293 Expressed (Native Glycosylation), Pro-form/Active form available, >95% purity, Endotoxin <1EU/µg, Sequence Verified. Includes S195A catalytic mutant for negative control. |
View KLK1 Products |
| Substrate Control | Kininogen (KNG1) Recombinant Protein Physiological substrate for enzymatic assays, HMWK/LMWK forms available. |
View KNG1 Products |
| Gene Delivery | KLK1 Premade Lentivirus ORF CMV promoter, Puromycin selection, for stable overexpression cell lines. |
View KLK1 Products |
| Detection Antibody | Anti-KLK1 Monoclonal Antibody Recombinant rabbit/human chimera, validated for WB/IHC/ELISA. |
View KLK1 Products |
| Functional Inhibitor | KLK1 Inhibitor Peptide (Competitive) Active site blocking, sequence verified by mass spec. |
View KLK1 Products |
| Validator | KLK1 siRNA Set (3 unique targets) For specific knockdown verification, >85% silencing efficiency. |
View KLK1 Products |
| Pathway Partner A | BDKRB2 (Bradykinin Receptor B2) Primary signaling receptor for KLK1-generated bradykinin. |
View BDKRB2 Products |
| Pathway Partner B | ACE (Angiotensin Converting Enzyme) Counter-regulatory enzyme degrading KLK1 product (bradykinin). |
View ACE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen vs Active Form Discrimination | Dual-format proteins available: Intact pro-KLK1 (Arg262-Ile391) and auto-processed active form. N-terminal sequencing verified by Edman degradation. |
| Species Cross-reactivity (Human/Mouse/Rat) | Ortholog panel (Human, Mouse, Rat KLK1) with >95% purity, sequence identity mapped for epitope conservation analysis. |
| Native Glycosylation Critical for Activity | HEK293 Expression system preserves N-glycosylation (Asn78, Asn84, Asn177) essential for enzymatic activity and stability. |
| Specificity vs KLK Family (KLK2/KLK3) | Family member proteins available (KLK2, KLK3) for off-target screening assays. |
| Enzymatic Activity Standardization | Chromogenic substrate (S-2266) activity lot-matched to international standards (IU/mg). |
| Lack of Assay Controls | Sequence Verified clinical benchmark antibodies included for reliable assay standardization. |
| Cell-Based Pathway Analysis | High-titer Lentivirus enables stable overexpression in primary endothelial or neuronal cell lines. |
Live KLK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic utility of KLK1 (Tissue Kallikrein) has historically centered around its role as a potent vasodilator and tissue-protective enzyme. Recombinant KLK1 therapies have found clinical success primarily in ischemic stroke and cardiovascular disorders. Current R&D focuses on enzyme replacement therapy for acute kidney injury (AKI) and chronic kidney disease (CKD), leveraging KLK1's ability to generate bradykinin and regulate renal hemodynamics. Key trends indicate a shift from cardiovascular indications (hypertension) toward renal protection, particularly in diabetic nephropathy and ischemia-reperfusion injury. The next wave of innovation targets combination therapies with ACE inhibitors (balancing the kallikrein-kinin system) and sustained-release formulations for subcutaneous delivery. The Kallikrein-Kinin system remains a high-value target for diabetic nephropathy and cardio-renal syndromes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Enzyme | Techpool (Kailikang), Bayer, Jiangsu Sinoregen (DM199) | Ischemic Stroke, Diabetic Nephropathy, Acute Kidney Injury | Enzymatic Activity Assay (Need High-Purity Active Protein) |
| Gene Therapy (AAV) | Various Academic/Biotech | Cardiovascular Disease, Hypertension, Heart Failure | Transduction Validation (Need reliable siRNA & Lentivirus) |
| Peptide Agonists/Modulators | Emerging Biotechs | Tissue Repair, Fibrosis | Receptor Binding/Cleavage (Need KNG1/KLK1 network proteins) |
| Small Molecule Inhibitors | Sun Pharmaceutical (pancreatitis focus) | Hereditary Pancreatitis, Inflammation | Enzymatic Inhibition Assays (Need active site vs allosteric mutant proteins) |
| Substrate Analogs | Biotech Startups | Fibrinolysis enhancement | Substrate Competition Assays (Need purified Kininogen substrates) |
Note: KLK1 is a soluble secreted serine protease (S1 peptidase family). Assay development requires careful attention to zymogen activation state and species-specific glycosylation patterns that affect enzymatic turnover.
Key Mutations and Functional Domains
KLK1 (UniProt P06870) contains a Peptidase S1 domain and several documented mutations:
- rs5: Associated with a significant decrease in urinary kallikrein activity.
- rs5516: Not associated with changes in urinary kallikrein activity.
- rs5517: Documented in dbSNP.
These variants are critical for understanding genetic influences on KLK1 activity in disease contexts.